A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/426 (2006.01) A61K 31/427 (2006.01) A61K 31/4439 (2006.01) A61P 3/10 (2006.01) A61P 9/00 (2006.01)
Patent
CA 2436116
A method for the treatment or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance, in humans or non-human mammals, which method comprises the administration of an effective, non-toxic and pharmaceutically acceptable amount of PPARy agonist, such as Compound (I), or a pharmaceutically acceptable derivative thereof. Conditions associated with cardiac insulin resistance are: microvascular angina, atherosclerosis and congestive heart failure. Compounds include rosiglitazone, troglitazone, englitazone and pioglitazone.
Procédé de traitement ou de prévention de l'insulino-résistance cardiaque ou des états associés à l'insulino-résistance cardiaque chez les mammaliens humains ou non humains, qui comprend l'administration d'une quantité efficace, non toxique et pharmaceutiquement acceptable d'un agoniste de PPARy tel que le composé (I) ou un dérivé pharmaceutiquement acceptable de celui-ci. Les états associés à l'insulino-résistance cardiaque sont l'angine microvasculaire, l'athérosclérose et l'insuffisance cardiaque globale. Les composés comprennent la rosiglitazone, la troglitazone, l'englitazone et la pioglitazone.
Gowling Lafleur Henderson Llp
Smithkline Beecham P.l.c.
LandOfFree
Treatment and prevention of cardiac insulin resistance... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment and prevention of cardiac insulin resistance..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment and prevention of cardiac insulin resistance... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1807773